Jazz Pharmaceuticals PLC DEF 14A proxy statements

Jazz Pharmaceuticals plc announced its 2026 Annual General Meeting of Shareholders will be held on July 23, 2026, to vote on director elections, auditor ratification, executive compensation, and share issuance authorities.

Jazz Pharmaceuticals plc is reminding its employee-shareholders to cast their votes for the upcoming Annual General Meeting on July 24, 2025, with board and management recommending a 'FOR' vote on all proposals.

Jazz Pharmaceuticals plc announced the appointment of Renee Gala as its new President and Chief Executive Officer, effective August 11, 2025, alongside significant adjustments to her compensation and an increase in the Board of Directors' size.

Jazz Pharmaceuticals Public Limited Company has filed a Definitive Proxy Statement (DEFA14A) with the SEC, outlining information for an upcoming shareholder meeting.

Jazz Pharmaceuticals plc has announced its 2025 Annual General Meeting to be held on July 24, 2025, seeking shareholder approval for the election of four directors, ratification of KPMG as auditors, advisory approval of executive compensation, and renewal of authority to allot shares for cash without pre-emption rights.

Jazz Pharmaceuticals encourages its employee shareholders to vote on key proposals at the upcoming Annual General Meeting (AGM) on July 25, 2024.

Jazz Pharmaceuticals has filed a proxy statement with the Securities and Exchange Commission.

Jazz Pharmaceuticals will hold its 2024 annual general meeting of shareholders on July 25, 2024, to vote on director elections, auditor ratification, executive compensation, and other corporate matters.